Autoimmune hemolytic anemia screening

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia screening

CDC on Autoimmune hemolytic anemia screening

Autoimmune hemolytic anemia screening in the news

Blogs on Autoimmune hemolytic anemia screening

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Shyam Patel [2], Irfan Dotani [3]

## Overview[edit | edit source]

Screening for autoimmune hemolytic anemia is not currently done routinely.

## Screening[edit | edit source]

* Screening for autoimmune hemolytic anemia is not currently done routinely.
* The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated.
* However, screening is done for other conditions associated with hemolytic anemia, such as sickle cell disease.[1]
* One important manifestation of sickle cell disease is hyperhemolytic crisis, in which there is massive hemolysis.
* The United States and the United Kingdom have formal screening processes in place for sickle cell disease for newborns.
* Screening for sickle cell disease can prevent early childhood morbidity and mortality.
* Less developed countries, such as countries in Africa, do not have formal screening measures for sickle cell disease in place.[1]

## References[edit | edit source]

1. ↑ 1.0 1.1 Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M; et al. (2016). "Emerging point-of-care technologies for sickle cell disease screening and monitoring". Expert Rev Med Devices. 13 (12): 1073–1093. doi:10.1080/17434440.2016.1254038. PMC 5166583. PMID 27785945.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

Template:WikiDoc Sources